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PML fuses with retinoic acid receptor a (RARa) in the t(15;17) translocation that causes acute promyelo-
cytic leukemia (APL). In addition to localizing diffusely throughout the nucleoplasm, PML mainly resides in
discrete nuclear structures known as PML oncogenic domains (PODs), which are disrupted in APL and
spinocellular ataxia cells. We isolated the Fas-binding protein Daxx as a PML-interacting protein in a yeast
two-hybrid screen. Biochemical and immunofluorescence analyses reveal that Daxx is a nuclear protein that
interacts and colocalizes with PML in the PODs. Reporter gene assay shows that Daxx drastically represses
basal transcription, likely by recruiting histone deacetylases. PML, but not its oncogenic fusion PML-RARa,
inhibits the repressor function of Daxx. In addition, SUMO-1 modification of PML is required for sequestra-
tion of Daxx to the PODs and for efficient inhibition of Daxx-mediated transcriptional repression. Consistently,
Daxx is found at condensed chromatin in cells that lack PML. These data suggest that Daxx is a novel nuclear
protein bearing transcriptional repressor activity that may be regulated by interaction with PML.
Acute promyelocytic leukemia (APL) arises as a result of
chromosomal translocation involving the retinoic acid (RA)
receptor a (RARa) gene on chromosome 17 fused with either
the promyelocytic leukemia gene (PML) on chromosome 15,
the promyelocytic leukemia zinc finger gene (PLZF) on chro-
mosome 11, the nucleophosmin/B23 (NPM) gene on chromo-
some 5, or the nuclear mitotic apparatus gene (NuMA) on
chromosome 11 (30, 39). The t(15;17) translocation between
PML and RARa accounts for nearly all APL cases. This trans-
location creates an oncogenic fusion protein, PML-RARa,
which contains both the DNA-binding domain (DBD) and
ligand-binding domains of RARa and the N terminus of PML.
Transgenic mice that overexpress PML-RARa or PLZF-
RARa developed an APL-like phenotype (9, 21, 26), suggest-
ing that these fusion proteins are directly involved in APL
pathogenesis. Recent studies have focused on analyzing the
functional properties of PML-RARa and PLZF-RARa (20,
22, 25, 40) in order to understand the molecular basis of leu-
kemogenesis. Both fusion proteins form homodimers that bind
to RA response elements and interact with the nuclear recep-
tor corepressors SMRT (silencing mediator for retinoid and
thyroid hormone action) and N-CoR (nuclear receptor core-
pressor), which in turn recruit a histone deacetylase complex
(1, 27, 40, 46). Pharmacological concentrations of all-trans-RA
(atRA) induce dissociation of the corepressors from PML-
RARa, but not PLZF-RARa, due to the presence of an ad-
ditional, RA-insensitive corepressor-interacting surface on
PLZF. This differential degree of dissociation of corepressors
induced by atRA correlates with the ability of histone deacety-
lase inhibitors and atRA to induce terminal differentiation of
these two subtypes of APL cells. These findings indicate that
abnormalities in transcriptional repression by the oncogenic
fusion proteins may be involved in leukemogenesis.
PML belongs to a family of proteins characterized by the
presence of a RING finger domain (8). RING finger proteins
are implicated in transcriptional regulation, and some mem-
bers of the RING family are associated directly with chromatin
(53). Ablation and overexpression experiments suggest an im-
portant role of PML in the regulation of cell growth, hemato-
poietic cell differentiation, tumorigenesis, apoptosis, and RA
signaling (44, 63). In normal cells, PML is concentrated within
10 to 20 nuclear structures known as nuclear domains 10
(ND10), Kru¨ppel bodies, nuclear bodies, or PML-oncogenic
domains (PODs) (2, 17, 33, 59, 65). The POD structure is
disrupted in the t(15;17) translocated APL cells (17, 33, 65),
presumably through interaction of wild-type PML with PML-
RARa. Interestingly, the POD structure reorganizes upon
treatment with atRA or arsenic trioxide (As2O3), a process
that correlates with differentiation of APL cells, indicating that
the POD structure might affect promyelocyte differentiation.
In addition to PML, the POD contains several other pro-
teins, including the 100-kDa nuclear protein antigen (Sp100)
(2), the small ubiquitin-related modifier (SUMO-1 [41], also
known as PML-interacting clone 1 [PIC1] [7], ubiquitin-like 1
[UBL1] [57], or sentrin [48]), and the 140-kDa protein (Sp140)
(6). Sp100 is a nuclear antigen recognized by autoantibodies
from patients with primary biliary cirrhosis (62). Expression of
both PML and Sp100 are upregulated by interferon (23).
SUMO-1 was recently identified as a ubiquitin-like protein that
forms covalent conjugates with PML and Sp100 (7, 58). In
addition, the CREB-binding protein (CBP) and the retinoblas-
toma tumor suppressor (pRB) have been found in the PODs
(35, 61). Also, the PODs are targets of several viral proteins,
which alter POD structure (11, 14, 18). Although there is
evidence for POD’s role in transcriptional activation (15, 35),
DNA replication (19), apoptosis (51, 64), and viral infection
(14, 42), the precise function of PODs in these processes re-
mains unclear.
We have sought to understand the function of PODs
through identification of PML-interacting proteins that also
localize in the PODs. By using the yeast two-hybrid system, we
identified SUMO-1 and the Fas-binding protein Daxx (68)
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(J. D. Chen and R. M. Evans, unpublished data). Daxx has
been shown to promote Fas-mediated apoptosis through acti-
vation of the Jun NH2-terminal kinase (JNK) and JNK kinase
kinase ASK1 (apoptosis signal-regulating kinase 1) (12). Re-
cent data suggest that Daxx is not sufficient for Fas-mediated
apoptosis, since a Fas mutant that selectively binds to Daxx but
not the Fas-adaptor death domain-containing protein (FADD/
MORT1) failed to induce apoptosis (13). Other evidence sug-
gests that Daxx may interact with the centromeric protein-c
(CENP-C) and may bind to a steroidogenic factor 1 (SF-1)-like
DNA element (32, 50). Therefore, the exact mechanism by
which Daxx regulates Fas-mediated apoptosis may involve nu-
clear processes.
In the present study, we have characterized both biochemi-
cal and functional interactions between Daxx and PML. Daxx
resides primarily in the cell nucleus, where it forms a complex
with PML. Confocal immunofluorescence data demonstrate
that Daxx colocalizes with PML in the PODs, and such colo-
calization persists in NB4 APL cells (36) before and after
treatment with atRA and As2O3. Daxx possesses strong tran-
scriptional repressor activity and appears to interact directly
with histone deacetylases. Intriguingly, overexpression of PML
inhibits Daxx-mediated transcriptional repression and, in cells
that lack PML, Daxx is preferentially associated with con-
densed chromatin. Our data reveal a new role for Daxx in
transcriptional repression and suggest a novel function of PML
and the POD structure in the suppression of transcriptional
repression.
MATERIALS AND METHODS
Yeast two-hybrid system. The screening of PML-interacting proteins was con-
ducted by the yeast two-hybrid system by using the Y190 strain as previously
described (16). The Gal4 DBD (amino acids 1 to 147) fusion of full-length PML
(29) was constructed in the yeast vector pAS1 (16). The resulting Gal4 DBD-
PML fusion protein was used as bait to screen a Gal4 activation domain (AD)-
fused human B-lymphocyte cDNA library in the pACT expression vector (16).
About 106 yeast transformants were screened on selection plates containing 50
mM 3-aminotriazole (Sigma). For ligand treatment, the culture was incubated in
the presence of ligand or solvent (control) for 24 h before measuring the b-ga-
lactosidase (b-Gal) activity.
Biochemical cell fractionation. HeLa cells (2 3 106) were harvested into 500
ml of CLB buffer (10 mM HEPES, 10 mM NaCl, 1 mM KH2PO4, 5 mM
NaHCO3, 1 mM CaCl2, 0.5 mM MgCl2)–5 mM EDTA–1 mM phenylmethylsul-
fonylfluoride–proteinase inhibitors. Cells were allowed to swell for 5 min on ice,
Dounce homogenized 35 times, and centrifuged at 7,500 rpm for 5 min to pellet
nuclei and debris. The supernatant (cytosol plus plasma membrane) was then
spun at 25,000 rpm for 30 min to pellet the membrane. The nucleus-debris pellet
was resuspended in 1 ml of TSE buffer (10 mM Tris, pH 7.5; 300 mM sucrose;
1 mM EDTA) and Dounce homogenized 30 times, followed by centrifugation at
5,000 rpm for 5 min. The pellet was resuspended and washed twice to obtain the
final nucleus pellet. Equal amounts of protein in each fraction were analyzed
Western blotting.
Western blotting. Western blotting was conducted by using the enhanced
chemiluminescence reagents according the manufacturers’ recommendation
(Amersham). The affinity purified anti-Daxx polyclonal antibodies were raised
against glutathione S-transferase (GST)-Daxx (amino acids 556 to 740) fusion
protein and subsequently purified with the GST-Daxx protein column as de-
scribed earlier (24). Anti-Gal4-DBD antibody was purchased from Santa Cruz,
and anti-HDAC1 antibody was from Upstate Biotechnology.
Co-IP. Coimmunoprecipitation (Co-IP) was conducted according to a stan-
dard procedure by using the protein A-agarose beads (Santa Cruz) (24). Nuclear
extracts were prepared as described earlier (3). HeLa and NB4 cells were lysed
in cell lysis buffer (0.4 M NaCl, 0.2 mM EGTA, 10% glycerol, 1% NP-40), and
cell extracts were precleared by incubating them with protein-A agarose beads
for 1 h at room temperature. The affinity-purified IP antibodies were conjugated
with protein A-agarose beads in cell lysis buffer for 2 h at room temperature. The
antibody-protein A-agarose was collected by brief centrifugation and incubated
with cell extracts (100 mg) overnight at 4°C. The precipitates were collected by
centrifugation and washed five times with excess phosphate-buffered saline con-
taining 0.1% NP-40. The final precipitate was dissolved in sodium dodecyl sulfate
A (SDS) sample buffer and analyzed by SDS-polyacrylamide gel electrophoresis
(PAGE) and Western blotting.
Immunofluorescence and confocal microscopy. Cells were grown on cover
glasses (VWR Scientific), fixed in a methanol-acetic acid (1:1) mixture on dry ice
for 2 min and processed for immunofluorescence staining as described elsewhere
(17). For NB4 cells, the cover glasses were coated with poly-L-lysine before
seeding the cells. After immunostaining, cell nuclei were stained with DAPI
(49,6-diamidino-2-phenylindole dihydrochloride hydrate) (Sigma). Confocal mi-
croscopy was conducted with a Leica TCS SP spectral laser scanning confocal
microscope. Channel cross-talk was avoided by reducing the intensity of the
excitation laser beam in the absence of the other excitation laser. Standard
epifluorescence microscopy was performed on an Olympus IX-70 microscope
equipped with a back-illuminated cool charge-coupled device (CCD) camera
(Princeton Instruments), and the image was processed by using the MetaMorph
software (Universal Imaging Corp.).
Transient-transfection assay. Transient transfection was conducted using a
standard calcium phosphate precipitate method as described earlier (3). Cul-
tured cells were maintained in Dulbecco modified Eagle medium or RPMI
medium (for NB4 cells) supplemented with 10% fetal bovine serum (Gibco).
Twelve hours prior to transfection, 2 3 104 cells were plated in each well of
12-well plates. Transfected cells were refed with fresh media and harvested 36 to
48 h after transfection. Transfected cells in each well were lysed and processed
for luciferase and b-Gal assay as described elsewhere (38). The luciferase activity
was determined with an MLX plate luminometer (Dynex) and normalized with
the cotransfected b-Gal.
Far-Western blot. GST fusion proteins were expressed in DH5a cells and
purified by standard glutathione agarose beads according to manufacturer’s
recommendation (Pharmacia). The purified proteins were separated by SDS-
PAGE and electroblotted onto a nitrocellulose filter in transfer buffer (25 mM
Tris-HCl, pH 8.3; 192 mM glycine; 0.01% SDS). Proteins were denatured with 6
M guanidine hydrochloride (GnHCl) and renatured by stepwise dilution of
GnHCl. Filters were blocked and hybridized overnight with 35S-labeled protein
as described elsewhere (38). The membrane was then washed three times with
hybridization buffer, and the bound probe was detected by autoradiography.
GST pull-down assay. The GST pull-down assay was conducted according to
a protocol as described earlier (24). Briefly, 5 mg of glutathione agarose-protein
beads was incubated with 5 ml of in vitro-translated 35S-labeled protein with
moderate shaking at 4°C overnight in binding buffer (20 mM HEPES, pH 7.7; 75
mM KCl; 0.1 mM EDTA; 2.5 mM MgCl2; 0.05% NP-40; 1 mM dithiothreitol; 1
mg of bovine serum albumin per ml). The bound protein was washed three times
with the binding buffer, and the beads were collected by centrifugation. The
bound protein was eluted in SDS sample buffer and analyzed by SDS-PAGE and
autoradiography.
Site-directed mutagenesis. Site-directed mutagenesis was conducted by using
the Quick-Change site-directed mutagenesis kit according to manufacturer’s
instruction (Stratagene). A mammalian hemagglutinin (HA)-PML vector was
used as a template, and mutagenesis was conducted in three rounds consecutively
on the same template. The mutated construct was confirmed by DNA sequencing
by using dideoxynucleotide chain-termination reactions and Sequenase (U.S.
Biochemicals).
RESULTS
Identification of Daxx as a PML-interacting protein. In the
yeast two-hybrid screen, we identified a PML-interacting clone
that encodes the C-terminal 184 amino acids of Daxx (32, 50).
Yeast two-hybrid assay shows that this Daxx clone interacts
with Gal4 DBD fusions of both PML and PML-RARa but not
SP100 (Fig. 1A), suggesting that Daxx may be a PML-interact-
ing protein. Since atRA binds to PML-RARa in a way similar
to that of wild-type RARa (4), we determined the effect of
atRA on interaction between Daxx and PML-RARa (Fig. 1B).
atRA inhibits the two-hybrid interaction between Daxx and
PML-RARa efficiently and in a dose-dependent manner. The
inhibition of binding is slightly more sensitive with the long
form of PML-RARa than with the short form, a finding con-
sistent with the higher affinity of the long form of PML-RARa
for atRA (4). This atRA-dependent inhibition of binding is
specific, for atRA has no effect on the interaction between
PML and Daxx while it enhances the interaction between
PML-RARa and the coactivator RAC3 (38). Also, the thyroid
hormone triiodothyronine that does not bind PML-RARa also
has no effect on the interaction between Daxx and PML-
RARa. These data suggest that Daxx is a PML-interacting
protein that may also associate with the oncoprotein PML-
RARa in the absence of atRA.
Daxx forms a complex with PML in vivo. In addition to
being diffusely distributed in the cytoplasm, PML is mainly a
nuclear protein, while Fas is a transmembrane cell surface
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receptor. Since Daxx interacts with both PML and Fas, it is
important to determine whether Daxx is a nuclear or cytoplas-
mic protein. We analyzed the subcellular distribution of Daxx
by using biochemical fractionation followed by Daxx immuno-
blotting. In this assay, Daxx cofractionates primarily with nu-
clear fraction, with a minority also present in the cytosolic and
membrane fractions (Fig. 1C). Control antibodies against the
cytoplasmic protein b-tubulin and the nuclear protein poly-
comb hPc2 (55) show no cross-contamination between the
cytoplasmic and nuclear fractions. All of these proteins were
detected in the membrane fraction, presumably because this
fraction also contains insoluble organelles involved in protein
synthesis and transportation. These results demonstrate that
Daxx resides mainly in the cell nucleus, suggesting that Daxx
may interact with PML in the nucleus.
To confirm that the interaction between Daxx and PML also
occurs in mammalian cells, we performed Co-IP assays from
HeLa and NB4 cell extracts (Fig. 1D). Both anti-Daxx and
anti-PML antibodies, but not preimmune serum, efficiently
coimmunoprecipitate endogenous Daxx. These data suggest
that Daxx may form a stable complex with PML in vivo. In the
immunoprecipitates of Daxx and PML antibodies, we also de-
tected weak signals of the 90-kDa PML and two SUMO-1-
conjugated forms of PML (data not shown), confirming the
presence of PML in the IP. We also attempted to demonstrate
an interaction between Daxx and PML in vitro in GST pull-
down and far-Western assays, but all experiments failed to
show a convincing interaction. We reasoned that this might be
due to the fact that PML is extensively modified by SUMO-1 in
FIG. 1. Interaction between Daxx and PML in vivo. (A) Interaction of Daxx with PML in yeast two-hybrid system. The average b-Gal activities of three
transformants expressing the indicated combinations of Gal4 AD and DBD fusion proteins were determined as described in Materials and Methods. The AD-Daxx
fusion protein contains amino acids 556 to 740 of human Daxx. The DBD fusion proteins contain full-length PML-1, SP100, and PML-RARa short form, respectively.
The minus sign indicates empty vector alone. (B) atRA disrupts the interaction between Daxx and PML-RARa. The effect of atRA on Daxx-PML-RAR interaction
was determined after a 24-h incubation of the culture in the presence of the indicated concentrations of respective ligands. Columns: 1, solvent only; 2, 1 nM; 3, 10
nM; 4, 100 nM; and 5, 1,000 nM. T3, 3,39,5-triiodo-L-thyronine. (C) Subcellular fractionation of Daxx. HeLa cells were fractionated into cytosolic, membrane, and
nuclear fractions, and an equal amount of protein was analyzed by Western blotting for Daxx (left panel). The distribution of the cytoplasmic protein b-tubulin and
the nuclear protein hPc2 in each fraction was also determined by immunoblotting to validate the fractionation. Two independent preparations of HeLa nuclear extracts
are shown. The right panel is a Coomassie blue-stained gel that shows the relative amount of proteins in each fraction used in the Western blot. (D) Co-IP of Daxx
with PML. NB4-cell extracts were immunoprecipitated with affinity-purified anti-Daxx and anti-PML antibodies, and the presence of Daxx in the immunoprecipitates
was determined by immunoblotting with anti-Daxx antibodies. The antibodies used for the IP and the Western blot (W.B.) are indicated.
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vivo (44, 45, 58) or that an additional factor may bridge the
interaction between PML and Daxx.
Daxx colocalizes with PML in the PODs. We then wished to
determine if Daxx colocalizes with PML in the PODs in order
to provide further evidence for a physiological interaction be-
tween Daxx and PML. Confocal immunofluorescence micros-
copy using affinity-purified anti-Daxx antibodies reveals dis-
crete nuclear structures in interphase HEp2 cells, in addition
to an evenly distributed nucleoplasmic staining (Fig. 2Aa).
Double immunostaining, together with use of anti-PML anti-
bodies, demonstrates that the Daxx foci colocalize perfectly
with the PODs in cell nuclei (Fig. 2Aa to d). Such colocaliza-
tion occurs in many different cell types, including HeLa,
HEK293, and A549 cells and normal human fibroblasts, sug-
gesting that colocalization between Daxx and PML may be a
common phenomenon in different cell types. The colocaliza-
tion has been confirmed by using antibodies against different
POD antigens, including SP100 and SUMO-1, as well as under
conditions that modify the POD structure, such as with inter-
feron, As2O3 treatments, and viral infections (unpublished
data). A three-dimensional topographic analysis of the colo-
calization between Daxx and PML demonstrates an extensive
colocalization between Daxx and PML in the PODs (Fig. 2B).
Colocalization of Daxx and PML in NB4 APL cells. We next
analyzed the distribution of Daxx in the NB4 APL cells (Fig.
2C), in which the PODs are disrupted into “microparticulate”
structures. Similar to PML, Daxx is also disrupted in the NB4
cells, in which it remains colocalized with PML. The presence
A
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FIG. 2. Daxx colocalizes with PML at the PODs. (A) Confocal immunofluorescence analysis of endogenous Daxx and PML. HEp2 cells were fixed and
immunostained with affinity-purified rabbit anti-Daxx polyclonal antibodies and mouse anti-PML 5E10 monoclonal antibodies as described in Materials and Methods.
The sample was analyzed by use of a confocal microscope. Panels a and b show the signals of Daxx (green) and PML (red) on a single confocal section. Panel c shows
colocalization (yellow signals) of Daxx and PML in the merged image. Panel d is a differential interference contrast image showing the surfaces of the cells and nuclei.
Bar, 10 mm. (B) Three-dimensional presentation of the colocalization between Daxx and PML. Total of 32 consecutive z-sections at increments of 0.08 mm were
reconstructed into a three-dimensional image by using the Leica confocal software. The right and left projected images were rotated 4.5° at opposite directions along
the x (horizontal) axis. Yellow represents the colocalization between Daxx (green) and PML (red). (C) Colocalization of Daxx and PML in APL cells. NB4 cells were
plated on cover glasses coated with poly-L-lysine. The control (untreated), atRA-treated (1 mM for 72 h), and As2O3-treated (1 mM for 72 h) cells were fixed and
immunostained with anti-Daxx polyclonal and anti-PML monoclonal antibodies. Colocalization of Daxx and PML was revealed by confocal laser microscopy (except
for the untreated cells).
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FIG. 3. Modulation of promoter activity by Daxx. (A) Transcriptional repression by Gal-Daxx. Recruitment of Daxx to a promoter via Gal4-DBD results in
inhibition of basal transcription in a dose-dependent manner. Transient transfection was conducted in HEK293 cells with increasing concentrations (nanograms) of
Gal-Daxx as indicated. The relative fold repression of the basal promoter activity in the presence of Gal-Daxx was compared to that of Gal4-DBD alone. The bottom
panels show immunoblots with anti-Gal4-DBD antibodies of the transfected fusion protein at indicated concentrations of expression vector. (B) Daxx represses basal
transcription as strong as PML-RARa. HEK293 cells were transfected with equal amounts (250 ng) of each expression vector, and the relative repression was
determined as described in Materials and Methods. The results show that Gal-Daxx represses basal transcription as strongly as Gal-PML-RARa. (C) Requirement of binding
sites for transcriptional repression by Gal-Daxx. HEK293 cells were transfected with 250 ng of Gal-Daxx or Gal4-DBD alone, and the effects on the promoter activities of
Gal-tk-luciferase (luc) and tk-luc reporters were determined. The Gal-tk-luc reporter contains four copies of Gal4-binding sites in front of the minimal tk promoter,
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of PML-RARa fusion protein in the microparticulate struc-
tures (17) supports the observed interaction between Daxx and
PML-RARa (Fig. 1). Upon atRA treatment, PML-RARa is
degraded in NB4 cells (47), and these microparticulate struc-
tures reorganize into normal size of the PODs (17, 65), where
Daxx and PML remain colocalized. The colocalization be-
tween Daxx and PML is more evident in NB4 cells treated with
As2O3, in which larger and fewer PODs are observed. These
results suggest that Daxx and PML colocalize in APL NB4
cells, and such colocalization persists after reorganization of
the PODs induced by atRA or As2O3.
Daxx represses basal transcription. Several POD-associated
proteins, including PML, are implicated in transcriptional reg-
ulation (for reviews see references 34 and 39). Since Daxx
interacts with PML and localizes at the PODs, we decided to
test whether Daxx might regulate transcription. Transfection
of the Gal4-DBD full-length Daxx fusion protein (Gal-Daxx)
in HEK293 cells strongly inhibits basal transcription of the
Gal4-tk-luciferase reporter in a dose-dependent manner (Fig.
3A, top). Western blotting using anti-Gal4 DBD antibodies
confirms increased expression of Gal-Daxx in transfected cells
in the presence of higher concentrations of DNA (Fig. 3A,
bottom). Comparison of Daxx-mediated transcriptional re-
pression with that of PML-RARa fusion proteins indicates
that Daxx represses as strongly as the PML-RARa oncopro-
tein (Fig. 3B). Moreover, repression by Gal-Daxx requires
Gal4-binding sites (Fig. 3C) and occurs in multiple cell types
(Fig. 3D), demonstrating the specificity of the observed Daxx-
mediated transcriptional repression.
We attempted to determine the sequences in Daxx that are
responsible for the repression activity by standard deletion
analysis (Fig. 3D). Progressive deletion from the C terminus to
residue 124 gradually reduces the repression activity of Daxx in
a cell-type-dependent manner. Deletions of the N terminus
and several other mutants also show a significant decrease in
repression. Equal expression of these Gal-Daxx deletion pro-
teins in transfected cells is confirmed by Western blotting using
the anti-Gal4 DBD antibodies (Fig. 3E). These data suggest
that multiple regions of Daxx may be important for transcrip-
tional repression in a cell-type-dependent manner.
Daxx was previously isolated in a yeast one-hybrid screen
using a reporter containing a SF-1-like element (32). We de-
cided to investigate whether Daxx can repress transcription
from a promoter containing the SF-1-like element in a tran-
sient-transfection assay (Fig. 3F). As expected, overexpression
of wild-type Daxx represses basal transcription from the SF1-
tk-luciferase reporter that contains four copies of the SF1-like
element, while it has little effect on the tk-luciferase reporter
lacking the SF-1 sites. These data indicate that Daxx may
repress the basal transcription of natural promoters containing
SF1-like elements, a result consistent with the strong repressor
activity observed with the Gal-Daxx fusion protein.
Daxx interacts with HDACs. Histone deacetylation has been
demonstrated to play a central role in transcriptional repres-
sion by inducing chromatin assembly and condensation (49,
66). To determine whether histone deacetylation is required
for Daxx-mediated transcriptional repression, we analyzed the
interaction between Daxx and the three available human his-
tone deacetylases (HDACs) (67). The three human HDACs
are highly conserved in structure and function. All of them
repress basal transcription in the Gal4-DBD fusion assay, and
all display histone deacetylase activity (67). Far-Western anal-
yses demonstrate interactions between Daxx and all three
GST-HDAC fusion proteins, but not GST alone, while PML
and SP100 show no interaction with any of these GST-HDACs
under the assay conditions (Fig. 4A and B and data not
shown). A positive control shows that PML interacts efficiently
with GST-PML under identical conditions (Fig. 4C). Further-
more, a Daxx mutant (amino acids 400 to 657) that possesses
weak repression activity also does not interact with HDAC1
(Fig. 4C). These data support a role for HDAC interaction in
Daxx-mediated transcriptional repression. The interaction be-
tween Daxx and HDAC1 is further confirmed in a GST pull-
down assay (Fig. 4D), in which GST-HDAC1, but not GST
alone, precipitates about 20% of input 35S-labeled Daxx.
Moreover, an interaction between Daxx and HDAC1 in vivo is
also observed by Co-IP of HeLa nuclear extracts (Fig. 4E), in
which HDAC1 coimmunoprecipitates with Daxx antibodies
but not with the preimmune serum. Together, these experi-
ments provide strong evidence that Daxx and HDACs interact
in vitro and in vivo.
HDAC inhibitor reverses Daxx-mediated repression. The
physical interaction observed between Daxx and HDAC sug-
gests that Daxx may recruit a HDAC corepressor complex to
repress basal transcription via histone deacetylation and chro-
matin condensation. To provide more evidence for this possi-
bility, we assayed the effect of a histone deacetylase inhibitor,
trichostatin A (TSA), on the repressor activity of Gal-Daxx in
a transient-transfection assay (Fig. 4F). As expected, TSA re-
verses transcriptional repression by Gal-Daxx in a dose-depen-
dent manner, while it has little effect on Gal4-DBD alone
under identical conditions. These data indicate that histone
deacetylation is involved in transcriptional repression by Daxx.
Inhibition of Daxx-mediated transcriptional repression by
PML. Since Daxx was identified as a PML-interacting protein
and subsequently demonstrated to possess strong transcrip-
tional repression activity, we decided to investigate the role of
PML in the regulation of transcriptional repression by Daxx.
To do this, Gal-Daxx was cotransfected with increasing
amounts of full-length PML into HEK293 cells and the activity
of the luciferase reporter was measured (Fig. 5A). As observed
above, Gal-Daxx represses reporter expression strongly when
compared to the Gal4-DBD alone (Fig. 5A, compare lanes 1
and 6). Interestingly, coexpression of increasing amounts of
PML inhibits this repression in a dose-dependent manner,
abolishing nearly all of the repressor function of Gal-Daxx
(lanes 2 to 5). This effect is specific to Gal-Daxx, for cotrans-
fection of PML with the Gal4-DBD alone has little effect on
reporter activity (lanes 7 and 8). These data suggest that PML
may inhibit Daxx-mediated transcriptional repression.
Similar experiments were then performed to determine if
PML-RARa might also regulate the function of Gal-Daxx.
while the tk-luc lacks the binding sites. (D) Mapping of the Daxx sequences required for repression. Schematic presentation of Gal-Daxx deletion mutants and their
effects on promoter activity in HEK293, HeLa, and CV-1 cells are summarized. The two acidic regions are indicated by black bars, and the two potential nuclear
localization signals are marked with diamonds. The bottom graph shows a column presentation of the repression activity of various Gal-Daxx deletion mutants in
HEK293 cells. (E) Expression of Gal-Daxx mutants in transfected cells. The transfected lysates were analyzed by immunoblotting by using mouse anti-Gal4-DBD
monoclonal antibodies. The top band in each lane represents the expected molecular weights of the Gal-Daxx mutants, except for Gal-Daxx (125-215), where the lower
band is the expected product. The deviation in protein expression level was compensated by normalization of luciferase activity with the coexpressed b-Gal activity. (F)
Inhibition of basal transcription from a natural promoter by Daxx. Wild-type Daxx was transfected into HEK293 cells together with either the SF1-tk-luciferase or
tk-luciferase reporter. The fold repression of the luciferase activity at increasing concentrations (micrograms) of Daxx is presented.
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When either the short or long forms of PML-RARa were
cotransfected with Gal-Daxx, the repression activity of Gal-
Daxx was unchanged (Fig. 5B). Thus, despite the observation
that both PML and PML-RARa interact with Daxx, only PML
can inhibit the ability of Daxx to repress transcription, suggest-
ing a differential role of PML and its oncogenic fusion protein
in regulation of Daxx function.
PML recruits Daxx to the POD. To elucidate the mechanism
by which PML blocks Daxx-mediated transcriptional repres-
sion, immunofluorescence microscopy was used to investigate
the subcellular localization of Gal-Daxx upon coexpression of
PML. In these experiments, HEp2 cells were transiently trans-
fected with Gal-Daxx in the absence or presence of HA-PML
and subsequently stained with the mouse anti-Gal4-DBD and
FIG. 4. Interaction of Daxx with HDACs. (A) 35S-labeled protein probes used in the far-Western assays. In vitro-translated [35S]methionine-labeled Daxx, PML,
and SP100 were analyzed by SDS-PAGE and detected by autoradiography. (B) Far-Western analysis of interaction between Daxx and HDACs. The top panel shows
the Coomassie blue-stained proteins used in the far-Western assay. The middle panel shows the far-Western blot of GST-HDACs with the 35S-labeled Daxx probe. The
bottom panel shows the far-Western blot with the 35S-labeled PML probe. (C) PML interacts with GST-PML in the far-Western assay. A positive control showing that
PML interacts with GST-PML in the far-Western assay was conducted under conditions identical to those for panel B. A far-Western blot showing that the Daxx mutant
(400-657) fails to interact with GST-HDAC1 fusion protein. (D) GST pull-down assay showing interaction between GST-HDAC1 and Daxx. The input 35S-labeled Daxx
contains one-third of the lysate used in the pull-down reaction, which was conducted as described in the Materials and Methods. (E) Co-IP of HDAC1 and Daxx. HeLa
nuclear extracts were incubated with affinity-purified anti-Daxx antibody or an equal concentration of the preimmune serum. The immunoprecipitates were resolved
by SDS-PAGE and analyzed by Western blot by using anti-HDAC1 polyclonal antibodies. (F) TSA reverses transcriptional repression by Gal-Daxx. HEK293 cells were
transfected with 250 ng of Gal4-DBD or Gal-Daxx mammalian expression vector together with a Gal4-dependent luciferase reporter. The fold repression by Gal-Daxx
at different concentrations of TSA was determined relative to that for the Gal4-DBD alone.
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rabbit anti-HA antibodies (Fig. 6A). When Gal-Daxx was over-
expressed alone in HEp2 cells, a fairly diffuse, evenly distrib-
uted staining pattern is observed in the nucleus (Fig. 6A, pan-
els a and b). Cotransfection of PML drastically alters the
distribution of Gal-Daxx, for nearly all of the Gal-Daxx protein
is recruited to the PODs, even at very high levels of Gal-Daxx
expression (Fig. 6A, panels c to f). Examination of the local-
ization of these enlarged PODs indicates that they occupy the
loose chromatin regions (Fig. 6Ae and f), similar to the local-
ization of PODs in the absence of PML overexpression. On the
contrary, cotransfection of PML does not recruit a Daxx mu-
tant (Gal-Daxx 1-502) lacking the PML-interacting domain to
the PODs (Fig. 6A, panels g to j), suggesting the specificity of
the assay. The abilities of PML to reverse Daxx-mediated re-
pression and to recruit Daxx to the PODs support the hypoth-
esis that PML may inhibit Daxx repressor function by seques-
tration of Daxx to the PODs.
PML recruits endogenous Daxx to the PODs. To address
whether recruitment of Daxx to the PODs also occurs at the
endogenous levels of Daxx, HA-PML was transfected into
HEp2 cells alone, and the localization of endogenous Daxx was
analyzed by immunofluorescence staining by using anti-Daxx
antibodies (Fig. 6B). Double immunostaining with anti-PML
antibodies reveals that overexpression of PML leads to accu-
mulation of endogenous Daxx to the PODs, resulting in re-
duced nucleoplasmic staining (Fig. 6B, panels a to c). Recruit-
ment of endogenous Daxx to the PODs is confirmed with
anti-HA antibodies that detect only the transfected HA-PML
(Fig. 6B, panels d to f). These data indicate that PML is able
to recruit endogenous nucleoplasmic Daxx to the PODs.
PML does not recruit HDAC1 to the PODs. So far we have
shown that Daxx interacts with HDACs (Fig. 4) and that PML
recruits Daxx to the PODs (Fig. 6). Accordingly, we wished to
determine the localization of HDAC and other corepressors,
such as SMRT, after PML overexpression. We find that over-
expression of PML does not alter the distribution of HDAC1
or SMRT (Fig. 6B, panels g to l), suggesting that PML may
segregate Daxx away from the corepressor complex. These
observations are consistent with a speculative mechanism by
which PML may inhibit transcriptional repression of Daxx via
sequestrating Daxx to the PODs.
SUMO-1 modification of PML is required for recruitment of
Daxx to the PODs. To determine if SUMO-1 modification of
PML may play a role in Daxx interaction, we generated a PML
mutant with all three SUMO-1 modification lysine residues
replaced with arginines by site-directed mutagenesis, based on
a prior study that mapped the modification sites (31). Upon
mutation of the three lysine residues of PML, we no longer
observe SUMO-1-conjugated forms of PML, even after treat-
ment of the transfected cells with As2O3 and coexpression with
SUMO-1 (Fig. 7A). This PML DSUMO mutant behaves sim-
ilarly to the wild-type protein in localizing to the PODs and in
enlarging the POD structure (Fig. 7B, panels a, d, and g).
Interestingly, while this SUMO-1-deficient mutant is capable
of localizing to PODs (panels b and c and panels d and e),
overaccumulation of the mutant protein in the PODs fails to
recruit nucleoplasmic Daxx (Fig. 7B, panels g to i). In contrast,
many of the enlarged PODs show reduced staining of Daxx
(Fig. 7B, panels g to i), suggesting that accumulation of the
unmodified form of PML in the PODs may lead to the disap-
pearance of Daxx in PODs. These data suggest SUMO-1 mod-
ification as being the underlying mechanism for the observed
interaction and colocalization between Daxx and PML in vivo.
SUMO-1 modification of PML is required for efficient inhi-
bition of Daxx-mediated repression. If our hypothesis that
recruitment of Daxx to the POD is inhibitory to its transcrip-
tional repression activity, one would predict that the PML
DSUMO mutant that fails to recruit Daxx to the PODs will be
defective in reversing transcriptional repression by Daxx. As
expected, we found that the PML DSUMO mutant is less
FIG. 5. Inhibition of Daxx-mediated transcriptional repression by PML. (A)
PML inhibits Daxx-mediated transcriptional repression. HEK293 cells were tran-
siently transfected with 100 ng of the Gal4-DBD or Gal-Daxx mammalian ex-
pression vectors in the absence or presence of the indicated amounts of PML
expression vector together with a Gal4-dependent luciferase reporter. Data are
presented as the percentage of maximum repression, where Gal-Daxx activity is
represented as 100% repression. (B) PML-RARa has no effect on Daxx-medi-
ated transcriptional repression. HEK293 cells were transiently transfected with
100 ng of the Gal4-DBD or Gal-Daxx mammalian expression vectors in the
absence or presence of expression vectors for PML, PML-RARa (short form), or
PML-RARa (long form), together with a Gal4-dependent luciferase reporter.
Data are presented as the percentage of maximum repression, where Gal-Daxx
activity is represented as 100% repression.
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effective in reversing transcriptional repression by Daxx in
transient transfection (Fig. 7C). Furthermore, we found that
the wild-type PML is incapable of reversing transcriptional
repression by Gal-HDAC1 and Gal-SMRTe (Fig. 7C). These
data correlate with immunofluorescence studies demonstrating
PML recruitment of Daxx, but not HDAC or SMRT, to the
POD, where it presumably is unable to repress transcription.
Daxx is associated with condensed chromatin in the absence
of PML. To provide further evidence that the demonstrated
functional interactions between Daxx and PML may be phys-
iologically relevant, we screened several cell lines to find a cell
type that may display abnormal localization of Daxx and/or
PML. We identified the embryonic carcinoma NT2 cell line;
upon staining with the anti-PML antibody, it is evident that
only a subset of these cells express PML and thus contain
PODs (Fig. 7D). In these cells, PML and Daxx colocalize in the
PODs (panels a to d). However, in cells lacking detectable
PODs, Daxx forms aggregates around the condensed chroma-
tin (Fig. 7D, panels e to h). Therefore, the localization and thus
the function of Daxx may depend on the level of PML in the
cell. At low PML levels, Daxx is concentrated at condensed
chromatin, where it may repress transcription. When PML
levels are higher, it is able to recruit Daxx away from con-
densed chromatin to the PODs, where Daxx no longer re-
presses basal transcription.
DISCUSSION
In the present study, we have identified Daxx as a PML-
interacting protein and characterized the functional interac-
tion between Daxx and PML. We find a majority of Daxx in the
nucleus of HeLa and HEp2 cells where it colocalizes with PML
in the PODs. In the NB4 APL cell line, Daxx is distributed in
the microparticulate structures that contain the PML-RARa
oncoprotein (17). The repressor function of Daxx is observed
upon tethering it to a reporter gene via a heterologous DNA
binding domain, as well as from a reporter containing a natural
SF1-like promoter element. The mechanism by which Daxx
represses basal transcription is found as involving histone
deacetylation, for Daxx interacts with HDACs in vitro and in
vivo and the histone deacetylase inhibitor, TSA, blocks the
repressor activity. Coexpression of PML reverses the transcrip-
tional repression by Daxx, which, in turn, correlates with the
recruitment of Daxx to the PODs. In addition, we show that
SUMO-1 modification of PML is required for both recruit-
ment of Daxx to the PODs and efficient inhibition of Daxx-
mediated repression. The physiological role of Daxx in tran-
scriptional repression is further supported by the observation
that Daxx associates with condensed chromatin in cells that
lack PML. Together, these data establish novel roles for Daxx,
as a transcriptional repressor, and for PML, as a protein that
can potentially regulate the repressor function of Daxx.
Consistent with our findings, Daxx has recently been iden-
tified as an inhibitor of transcriptional activation by Pax3, a
member of the homeodomain family of transcription factors
(28). Thus, Daxx not only is able to repress basal transcription,
as suggested from our data, but can also inhibit transcriptional
activation via interactions with DNA-binding transcription fac-
tors. While the exact mechanism of the inhibition of Pax3
transactivation by Daxx is unclear, our data elucidate the
mechanism of Daxx-mediated repression of basal transcription
as involving histone deacetylation. We observe Daxx localiza-
tion to condensed chromatin in NT2 cells that lack detectable
PML. Condensed chromatin is considered as a site of tran-
scriptional repression that also includes transcriptionally silent
centromeric heterochromatin. Other POD-associated pro-
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FIG. 6. Recruitment of Daxx to POD domains by overexpression of PML.
(A) Overexpression of PML recruits transfected Gal-Daxx into the PODs. Gal-
Daxx or Gal-Daxx (1-502) were transiently transfected into HEp2 cells in the
absence or presence of HA-tagged PML and subsequently stained with the
mouse anti-Gal4-DBD and rabbit anti-HA antibodies. Primary antibodies were
detected with rhodamine-conjugated anti-mouse immunoglobulin G and fluo-
rescein isothiocyanate-conjugated anti-rabbit immunoglobulin G secondary an-
tibodies and analyzed by immunofluorescence microscopy. Panels a and b show
diffuse nuclear staining of Gal-Daxx in the absence of PML. Panels c to f show
Gal-Daxx and HA-PML colocalization at the PODs. Panels g to j show that
HA-PML cannot recruit a Gal-Daxx (1-502) mutant lacking the PML-interacting
domain to the PODs. (B) Recruitment of endogenous Daxx but not HDAC1 and
SMRT to the PODs. HA-PML was transfected into HEp2 cells, and the local-
ization of endogenous Daxx, HDAC1, and SMRT was analyzed by immunoflu-
orescence microscopy. Panels a to c show colocalization of transfected and
endogenous PML with endogenous Daxx by using anti-PML monoclonal 5E10
and anti-Daxx rabbit polyclonal antibodies. Panels d to f show HA-PML and
Daxx colocalization by using the anti-HA monoclonal and anti-Daxx polyclonal
antibodies. Panels g to l demonstrate that HA-PML does not recruit HDAC1 or
SMRT to the PODs by using anti-HA, anti-HDAC1, or anti-SMRT antibodies.
Yellow signals in the overlay images indicate colocalization.
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FIG. 7. SUMO-1 modification of PML is required for sequestration of Daxx to the POD and inhibition of Daxx-mediated transcriptional repression. (A) The PML
DSUMO (DSU) mutant lacks SUMO-1 modification. This mutant was created by replacing all three lysines at residues 65, 160, and 490 with arginines. The wild-type
(WT) PML and the DSUMO mutant were transfected into HEK293 cells alone or in combination with a SUMO-1 expression vector. Cells were treated with 1 mM
arsenic trioxide (As2O3) for 6 h where indicated. The total cell lysates were analyzed by Western blotting by using anti-HA monoclonal antibodies. The upper bands
in the wild-type proteins represent SUMO-1 conjugated forms of PML. (B) The PML DSUMO mutant localizes to the PODs but fails to recruit Daxx. The HA-PML
DSUMO mutant was transfected into HEp2 cells and analyzed by immunofluorescence microscopy to detect localization of the transfected mutant protein and the
distribution of endogenous Daxx. Panels a to c show localization of the transfected HA-PML DSUMO mutant protein (detected by a HA antibody) in the PODs that
were revealed by a PML polyclonal antibody (1-14). Panels d to f show that the enlarged PODs in the HA-PML DSUMO mutant transfected cells do not result in
prominent recruitment of Daxx to the PODs. Panels g to i show that many enlarged PODs containing PML-DSUMO mutant have little or no Daxx protein. The 5E10
antibodies also detect PODs in untransfected cells that show smaller structures colocalized with Daxx foci. (C) The PML DSUMO mutant is deficient in reversing
transcriptional repression by Daxx. The transfection was conducted in HEK293 cells, and the initial fold repression mediated by the Gal4-DBD fusion proteins is as
indicated at the bottom. The y axis indicates the fold reversal of repression. The wild-type PML does not reverse transcriptional repression mediated by HDAC1 or
SMRTe. (D) Association of Daxx with condensed chromatin in cells that lack PODs. The human neuronal NT2 stem cells were analyzed by double immunofluorescence
staining with anti-Daxx polyclonal and anti-PML 5E10 monoclonal antibodies. The NT2 cells display heterogeneous staining for PML. In cells that contain normal PML
nuclear bodies (panels a to d), Daxx appears normal and shows complete colocalization with PML. In contrast, cells that contain only two or fewer PML nuclear dots
show aggregated Daxx surrounding the condensed chromatin areas stained with DAPI (panels e to h).
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teins, such as SP100, have been demonstrated to interact with
heterochromatin protein 1 (HP1) and also colocalize with cen-
tromeric chromatin (10, 54). Consistent with this idea, Daxx
has been shown to interact with CENP-C in a yeast two-hybrid
assay and partially to colocalize with interphase centromeres
(50). Also, Daxx has been shown to interact with DNA meth-
yltransferase 1, which plays a role in gene silencing (43).
Previous studies have implicated the PODs as sites of tran-
scriptional activation. For example, PML has been demon-
strated to interact with the transcription coactivator CBP and
recruit CBP to the PODs (15, 35). Furthermore, PML can
enhance the transactivation functions of both CBP and mem-
bers of the nuclear receptor superfamily (15). PML also in-
duces genes of the major histocompatibility complex, while
PML2/2 mice display reduced transactivation responses to
atRA (64, 69). Finally, the transcriptional activator Sp140 (5,
6) and nascent RNA (35) have been found in at least a subset
of PODs. Our findings that Daxx represses basal transcription
and PML inhibits such repressor activity suggest a new role for
the POD structure in gene regulation. The POD may enhance
transcription of target genes not only through recruitment of
activators but also through the inactivation of repressors such
as Daxx via recruitment by PML. Because other transcriptional
repressors, such as PLZF, pRB, and Sp100, have also been
found in the PODs, it will be interesting to determine if PML
can regulate the repressor activities of these proteins as well.
Our observations that PML-RARa can interact with Daxx
but not inhibit transcriptional repression by Daxx suggest a
potential role for Daxx in acute promyelocytic leukemia. Sup-
port for this hypothesis is evident in our finding that Daxx,
PML-RARa, and PML colocalize at diffusely distributed mi-
croparticulate structures in nucleus of the APL NB4 cells. The
PML-RARa fusion protein disrupts the POD structure in
these cells and, through its interaction with Daxx, may direct
Daxx to the microparticulate structures, where it is capable of
repressing gene expression. PML-RARa itself is a potent tran-
scriptional repressor, which acts via the recruitment of the
corepressors SMRT, N-CoR, and HDAC1 (40). The POD
structure is reorganized upon treatment of these cells with
atRA or arsenic trioxide, leading to the degradation of the
PML-RARa fusion protein and colocalization of Daxx and
PML in the PODs (47). Therefore, Daxx inactivation through
localization to the PODs may be critical to the differentiation
of normal hematopoietic cells. Since expression of the PML-
RARa fusion protein disrupts the integrity of the PODs, Daxx
may act as a constitutive repressor in the APL cells, which
along with the repressor function of PML-RARa, may block
expression of specific genes that are critical for cell differenti-
ation and culminate in the subsequent APL pathology.
Daxx was initially identified as a Fas-binding protein that
promoted Fas-mediated apoptosis via activation of the JNK
kinase cascade pathway (12, 68). Interestingly, PML has also
been found to be involved in apoptosis triggered by Fas, tumor
necrosis factor alpha, and type I and II interferons, possibly by
recruitment of the death effector Bax and cdk inhibitor p21
(37, 51, 64). In contrast, expression of PML-RARa prevents
apoptosis in response to these signals (51). Our findings, to-
gether with these reports, suggest that the regulation of Daxx
repressor function by PML may also be important in pro-
grammed cell death. Consistent with this possibility, several
transcriptional repressors are known to play a role in apopto-
sis. For example, the adenovirus E1B and the cellular Bcl-2
oncoprotein block p53-mediated apoptosis by inhibiting tran-
scriptional repression by p53, suggesting that p53 induces ap-
optosis via transcriptional repression (52, 56). In the case of
Daxx, PML may recruit it to the PODs, where it is inactivated,
thus allowing the expression of certain genes required for ap-
optosis. Conversely, PML-RARa might inhibit apoptosis in
APL cells through disruption of the PODs, thereby promoting
enhanced or constitutive repression of these target genes by
Daxx and the PML-RARa fusion protein itself, which leads to
the APL phenotype. Retinoic acid treatment would stimulate
degradation of PML-RARa and restoration of the POD struc-
ture (17, 47, 65). This would allow Daxx to be inactivated
through sequestration to the PODs and allow apoptosis to
proceed and would eventually lead to remission of the APL
phenotype. Because PML can shuttle between the nucleus and
cytoplasm (59, 60), it is possible that Daxx may be brought
along with PML to regulate cytoplasmic events relevant to
Fas-mediated apoptosis. However, a recent study reports that
the loss of Daxx leads to extensive apoptosis in early mouse
development (43), a result seemingly opposite to other findings
concerning the function of Daxx in apoptosis (12, 13, 68).
Therefore, the precise role of Daxx in apoptosis remains to be
further elucidated.
Our data provide strong evidence for the roles of PML and
the PODs in regulating the function of Daxx as a transcrip-
tional repressor. Daxx and PML interact in vivo and colocalize
in the PODs. Overexpression of PML recruits Daxx to the
PODs, which correlates with a complete inhibition of tran-
scriptional repression by Daxx. Although the detailed mecha-
nism of this inhibition of Daxx by PML remains to be deter-
mined, our data provide several possibilities. First, PML might
inactivate Daxx by transporting it to the PODs and separating
it from HDAC and putative target genes. In response to cer-
tain stimuli such as interferon, PML levels increase in the
PODs, which, via competition for Daxx binding or conforma-
tional change of Daxx upon PML binding, might result in the
dissociation of Daxx from HDAC and recruitment of Daxx, but
not HDAC, to the PODs. Confinement of Daxx in the PODs
would thus block access to target genes, whose expression level
would then increase to at least the basal level in the absence of
Daxx repression. Our findings that PML overexpression results
in increased Daxx levels in the PODs, while having no effect on
HDAC1 distribution or repression by HDAC1, support this
possibility. Alternatively, the increased PML levels may disso-
ciate HDAC from Daxx and recruit both Daxx and its putative
target genes, but not HDAC, to the PODs. Because Daxx
requires HDAC and histone deacetylation for its repressor
activity, the target genes may be expressed in the absence of
HDAC. The presence of transcriptional activators in the PODs
would facilitate transcription of target genes. With either pos-
sibility, it is evident that the POD is involved in maintaining the
balance of Daxx function, depending on the PML level. At
normal, physiological levels of PML, Daxx might repress tran-
scription at areas of condensed chromatin. However, with in-
creased PML expression, more Daxx is recruited to the PODs,
thus reducing its overall repression activity. Although the pre-
cise mechanism of the inhibition of Daxx repression by the
PODs awaits further investigation, our data clearly reveal a
novel connection between Daxx and PML in regulating tran-
scriptional repression that may play a critical role in acute
promyelocytic leukemia and apoptosis.
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